Astellas and Medivation reported a 10-month progression-free survival benefit for Xtandi (enzalutamide) versus Casodex (bicalutamide) in a Phase II clinical trial designed to satisfy requests for a head-to-head comparison of the androgen receptor inhibitors in metastatic castrate-resistant prostate cancer (mCRPC).
Like the Phase III PREVAIL trial results that supported US and EU approvals for Xtandi in the treatment of mCRPC...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?